Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Conclusions Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns. Patient summary Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection. Three-year safety follow-up of Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial patients with castration-resistant prostate cancer and symptomatic bone metastases revealed a continued low incidence of myelosuppression, minimal nonhematologic adverse events, and secondary malignancies (none related to treatment) in four radium-223 patients and three placebo patients.
CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States. PMID: 29469047 [PubMed - in process]
Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.Medscape Urology
February 23, 2018—(BRONX, NY)—Earlier this week, in a crowded conference room in the Price Center/Block Pavilion, members of the Einstein-Montefiore community hosted a special visit from U.S. Congressman Joseph Crowley (D-NY, 14th District). At his office’s request, Rep. Crowley met with more than a dozen BOLD Buddies, volunteer peer mentors who provide support for cancer patients and survivors in the Bronx. Members of the group shared their personal stories and explained commitment to offer their support, hope and encouragement to others facing cancer and treatment at all stages of disease.
Conclusions: Impaired fibrinolysis, mainly driven by plasminogen activator inhibitor-1 increase and thrombin activatable fibrinolysis inhibitor activation, is an early manifestation of sepsis and may precede the development of thrombocytopenia. Thrombin activatable fibrinolysis inhibitor level, in particular, proved to be an independent predictor of mortality, which may improve risk stratification of patients with severe sepsis.
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a doctor.
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Norton Healthcare is customizing treatment rooms for the best patient and provider experience.
Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.
e;ndez I, Rodríguez-Acosta A Abstract Crotamine is a cationic, non-enzymatic, protein integrating a minor family of myotoxins, composed of 42 amino acid residues, described in Viperidae and Crotalidae snake's families that has been used in neuroscience research, drug progressing and molecular diversity reports. Crotamine-like protein (CLP) from C.o.helleri venom was isolated in fraction 5 from 7 peaks obtained by sulfopropyl waters protein pak cationic exchange column. In tricine-SDS-PAGE under non-reduced conditions this CLP showed a single band of ~8 kDa molecular weight. CLP induced toxicity of K-56...